BNIP3L/NIX-mediated mitophagy: Future directions in Alzheimer's disease

Violina Kakoty1, Khang Wen Goh2, Prashant Kesharwani3

  • 1School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T Road, Phagwara, Punjab, India.

Brain Research
|September 29, 2025
PubMed

Insights

Stimulating BCL2-interacting protein 3 like (BNIP3L) may treat Alzheimer's Disease (AD). BNIP3L enhances mitophagy, a process crucial for clearing damaged mitochondria implicated in AD pathogenesis.

Area of Science:

  • Cell Biology
  • Neuroscience
  • Biochemistry

Background:

  • Mitochondrial dysfunction and impaired mitophagy are early indicators of Alzheimer's Disease (AD).
  • BNIP3L (also known as NIX) is a mitochondrial protein involved in mitophagy and apoptosis.
  • Reduced BNIP3L expression is observed in response to stress during Alzheimer's.

Purpose of the Study:

  • To review downstream proteins of BNIP3L that mediate mitophagy.
  • To highlight the role of healthy mitochondria and mitophagy in Alzheimer's Disease.
  • To discuss the therapeutic potential of BNIP3L in AD and other diseases.

Main Methods:

  • Literature review of recent findings on BNIP3L-mediated mitophagy.
  • Analysis of studies investigating BNIP3L expression and function in Alzheimer's models.
  • Synthesis of information on BNIP3L's role in mitochondrial health and disease.

Main Results:

  • BNIP3L stimulation upregulates mitophagy, showing therapeutic promise for Alzheimer's.
  • Downstream proteins of BNIP3L are critical for its mitophagy-inducing effects.
  • BNIP3L has implications beyond AD, including cardiovascular conditions and cancer.

Conclusions:

  • BNIP3L is a key regulator of mitophagy with significant therapeutic potential for Alzheimer's Disease.
  • Understanding BNIP3L's regulatory network is crucial for advancing AD research.
  • BNIP3L's multifaceted role underscores its potential as a therapeutic target in various diseases.